1403257-49-7

Basic information

• Product Name: Benzoic acid, 5-broMo-2-Methyl-3-[(tetrahydro-2H-pyran-4-yl)aMino]-, Methyl ester
• Synonyms: Benzoic acid, 5-broMo-2-Methyl-3-[(tetrahydro-2H-pyran-4-yl)aMino]-, Methyl ester;Methyl 5-Bromo-2-Methyl-3-((Tetrahydro-2H-Pyran-4-Yl)Amino)Benzoate
• CAS NO: 1403257-49-7
• Molecular Formula: C₁₄H₁₈BrNO₃
• Molecular Weight: 328.20162
• Mol File: 1403257-49-7.mol
• Article Data: 28

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzoic acid, 5-broMo-2-Methyl-3-[(tetrahydro-2H-pyran-4-yl)aMino]-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-broMo-2-Methyl-3-[(tetrahydro-2H-pyran-4-yl)aMino]-, Methyl ester(1403257-49-7)
• EPA Substance Registry System: Benzoic acid, 5-broMo-2-Methyl-3-[(tetrahydro-2H-pyran-4-yl)aMino]-, Methyl ester(1403257-49-7)

Safety Data

• Hazardous Substances Data: 1403257-49-7(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 5-broMo-2-Methyl-3-[(tetrahydro-2H-pyran-4-yl)aMino]-, Methyl ester is a chemical compound that is a methyl ester derivative of 5-bromo-2-methyl-3-[(tetrahydro-2H-pyran-4-yl)amino]benzoic acid. It is commonly used in the pharmaceutical industry as an intermediate for the synthesis of various drugs. Benzoic acid, 5-broMo-2-Methyl-3-[(tetrahydro-2H-pyran-4-yl)aMino]-, Methyl ester has potential applications in medicinal chemistry and drug discovery due to its structural features and pharmacological properties. It may also be used in research and development of new pharmaceutical compounds and in the production of certain types of medications.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 2081-44-9 Tetrahydro-pyran-4-ol 
• 1000342-11-9 2-methyl-3-amino-5-bromobenzoic acid methyl ester 
• 84302-42-1 2,3-dihydro-4H-pyran-4-one 
• 79669-49-1 5-bromo-2-methylbenzoic acid 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 220514-28-3 5-bromo-2-methyl-3-nitrobenzoic acid methyl ester 
• 107650-20-4 5-bromo-2-methyl-3-nitro-benzoic acid 
• 142-68-7 TETRAHYDROPYRANE 

Downstream Products

• 1403257-79-3 2-methyl-3-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-5-bromobenzoic acid methyl ester 
• 1403258-11-6 methyl 4-methyl-4'-(morpholinomethyl)-5-((tetrahydro-2H-pyran-4-yl)amino)-[1,1'-biphenyl]-3-carboxylate 

Relevant articles and documents

Preparation Method for Amide Compounds and Use Thereof in Medical Field

Provided are a preparation method for amide compounds and use thereof in medical field. Specifically, provided are small molecule amide compounds. Such compounds are inhibitors of enhancer homolog 2 (EZH2) of Zeste gene, and can be used for preventing and/or treating related diseases mediated by EZH2, including tumors, myeloproliferative diseases or autoimmune diseases.

Bifunctional compound capable of inducing PRC2 protein complex core subunit degradation, pharmaceutical composition and application

The invention discloses a bifunctional compound capable of inducing PRC2 protein complex core subunit degradation, a pharmaceutical composition and application. The bifunctional compound comprises a compound as shown in any one of formulas I-III, a pharmaceutically acceptable salt or prodrug thereof, a solvate thereof, a hydrate thereof, a polymorphic substance thereof, a tautomer thereof, a stereoisomer thereof or an isotope substituted compound thereof, wherein n in the formulas I-III is an integer from 1 to 10, X is O, N or S, and Y is O, H2 or S. The bifunctional compound can effectively induce degradation of a core subunit of a PRC2 protein complex, so that cancers mediated by the PRC2 complex and subunits thereof including EZH2, EED, SUZ12, RbAp46 and RbAp48 are treated, and the carcinogenic activity of the subunits of the PRC2 complex is completely blocked.

Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2

EZH2 mediates both PRC2-dependent gene silencing via catalyzing H3K27me3 and PRC2-independent transcriptional activation in various cancers. Given its oncogenic role in cancers, EZH2 has constituted a compelling target for anticancer therapy. However, current EZH2 inhibitors only target its methyltransferase activity to downregulate H3K27me3 levels and show limited efficacy because of inadequate suppression of the EZH2 oncogenic activity. Therefore, therapeutic strategies to completely block the oncogenic activity of EZH2 are urgently needed. Herein, we report a series of EZH2-targeted proteolysis targeting chimeras (PROTACs) that induce proteasomal degradation of PRC2 components, including EZH2, EED, SUZ12, and RbAp48. Preliminary assessment identified E7 as the most active PROTAC molecule, which decreased PRC2 subunits and H3K27me2/3 levels in various cancer cells. Furthermore, E7 strongly inhibited transcriptional silencing mediated by EZH2 dependent on PRC2 and transcriptional activation mediated by EZH2 independent of PRC2, showing significant antiproliferative activities against cancer cell lines dependent on the enzymatic and nonenzymatic activities of EZH2.